Actinogen Medical identifies 30% slowing of Alzheimer's progression in older patients
Published: 09:43 19 Nov 2026 AEDT
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has reported a 30% slowing of Alzheimer's disease progression among patients aged over 75 in its pivotal XanaMIA clinical trial, although its experimental treatment Xanamem failed to achieve statistical significance across the overall study population.
The Sydney-based biotechnology company released topline results from the 36-week trial involving 247 patients with mild to moderate Alzheimer's disease, identifying encouraging treatment responses in older participants.
Among patients over 75, 40% receiving Xanamem showed no disease progression compared with 22% receiving a placebo, a statistically significant difference.
The company also reported a 30% slowing of disease progression in this age group, although that measure did not reach statistical significance.
Across the full trial population, Xanamem delivered a modest improvement over placebo but failed to meet the study's primary endpoint.
Importantly, the treatment maintained a favourable safety profile throughout the 36-week trial, with no serious adverse events attributed to Xanamem.
Older patients show strongest response
The XanaMIA trial evaluated Xanamem, also known as emestedastat, as a once-daily oral treatment for Alzheimer's disease.
The trial measured disease progression using the Clinical Dementia Rating Scale – Sum of Boxes, which assesses cognitive and functional decline.
In patients older than 75, Xanamem produced a 0.39-point improvement over placebo after 36 weeks, representing a 30% reduction in disease progression.
The strongest finding came from the proportion of older patients whose disease remained stable throughout treatment.
Actinogen believes these results could support a treatment opportunity among older Alzheimer's patients, who account for more than 70% of people living with the disease.
The findings have also prompted the company to pursue additional patent protection covering Xanamem's use in older patients with more advanced Alzheimer's disease.
Extended trial delivers encouraging results
Actinogen has also identified early signs of sustained treatment benefits in the ongoing open-label extension phase of XanaMIA.
The first 29 participants to complete 24 weeks of active Xanamem treatment showed no average disease progression during that period.
The company will continue the extension study to assess longer-term treatment effects and safety.
Its next major clinical milestone is expected in the first quarter of 2027, when approximately 100 participants will have completed at least 24 weeks of treatment.
Actinogen also plans to examine the trial findings with potential pharmaceutical development partners, focusing particularly on the response among older patients.
Funding supports next development phase
Following the topline results, Actinogen has moved to conserve cash by suspending further Phase 3 expenditure while it reviews the clinical data and considers its development strategy.
The company holds A$18.9 million in cash, has no debt and expects its existing resources to support operations into 2028.
“Following our topline analysis of the XanaMIA trial we remain confident in the risk-benefit profile of Xanamem in mild to moderate Alzheimer’s disease, with notable findings of clinically significant disease slowing in older participants, who represent a poorly served and large segment of the market," Actinogen CEO Dr Steven Gourlay said.
"Our strong balance sheet provides optionality to fully explore the trial data with potential partners over the coming months and determine the optimal development path for Xanamem. We sincerely thank everyone for their ongoing support of Xanamem development including patients and their families living with Alzheimer’s disease, as well our shareholders.”
About Actinogen Medical
Actinogen Medical is an Australian clinical-stage biotechnology company developing treatments for neurological and neuropsychiatric disorders.
Its lead drug candidate, Xanamem, aims to reduce excessive cortisol activity in the brain by inhibiting the enzyme 11β-HSD1, which plays a role in regulating tissue cortisol levels.
Elevated cortisol has been linked to Alzheimer's disease progression and depression.
The company has evaluated Xanamem in eight clinical trials involving more than 500 participants, with potential applications in Alzheimer's disease and depression.
Xanamem remains an investigational treatment and has not received regulatory approval.